Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype

被引:131
作者
Carafa, Vincenzo [1 ]
Altucci, Lucia [1 ]
Nebbioso, Angela [1 ]
机构
[1] Univ Campania Luigi Vanvitelli, Dipartimento Med Precis, Naples, Italy
来源
FRONTIERS IN PHARMACOLOGY | 2019年 / 10卷
关键词
Sirtuins; epigenetics; cancer; EMT; cancer therapy; EPITHELIAL-MESENCHYMAL TRANSITION; SMALL-MOLECULE INHIBITOR; CELL LUNG-CANCER; PANCREATIC-CANCER; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; MITOCHONDRIAL SIRTUINS; HISTONE DEACETYLASE; SIRT1; DEACETYLASE; REGULATES SIRT1;
D O I
10.3389/fphar.2019.00038
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Sirtuins (SIRTs), class III histone deacetylases, are differentially expressed in several human cancers, where they display both oncogenic and tumor-suppressive properties depending on cellular context and experimental conditions. SIRTs are involved in many important biological processes and play a critical role in cancer initiation, promotion, and progression. A growing body of evidence indicates the involvement of SIRTs in regulating three important tumor processes: epithelial-to-mesenchymal transition (EMT), invasion, and metastasis. Many SIRTs are responsible for cellular metabolic reprogramming and drug resistance by inactivating cell death pathways and promoting uncontrolled proliferation. In this review, we summarize current knowledge on the role of SIRTs in cancer and discuss their puzzling dual function as tumor suppressors and tumor promoters, important for the future development of novel tailored SIRT-based cancer therapies.
引用
收藏
页数:14
相关论文
共 175 条
[1]  
Aggarwal BB, 2004, ANTICANCER RES, V24, P2783
[2]   Altered Sirtuin 7 Expression is Associated with Early Stage Breast Cancer [J].
Aljada, Ahmad ;
Saleh, Ayman M. ;
Alkathiri, Moath ;
Shamsa, Heba Bani ;
Al-Bawab, Ahmad ;
Nasr, Amre .
BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2015, 9 :3-8
[3]   Upregulation of SIRT6 predicts poor prognosis and promotes metastasis of non-small cell lung cancer via the ERK1/2/MMP9 pathway [J].
Bai, Lihong ;
Lin, Gengpeng ;
Sun, Longhua ;
Liu, Yangli ;
Huang, Xinyan ;
Cao, Chuangjie ;
Guo, Yubiao ;
Xie, Canmao .
ONCOTARGET, 2016, 7 (26) :40377-40386
[4]   SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation [J].
Barber, Matthew F. ;
Michishita-Kioi, Eriko ;
Xi, Yuanxin ;
Tasselli, Luisa ;
Kioi, Mitomu ;
Moqtaderi, Zarmik ;
Tennen, Ruth I. ;
Paredes, Silvana ;
Young, Nicolas L. ;
Chen, Kaifu ;
Struhl, Kevin ;
Garcia, Benjamin A. ;
Gozani, Or ;
Li, Wei ;
Chua, Katrin F. .
NATURE, 2012, 487 (7405) :114-+
[5]   Therapeutic potential of resveratrol:: the in vivo evidence [J].
Baur, Joseph A. ;
Sinclair, David A. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (06) :493-506
[6]   Identification of a small molecule inhibitor of Sir2p [J].
Bedalov, A ;
Gatbonton, T ;
Irvine, WP ;
Gottschling, DE ;
Simon, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (26) :15113-15118
[7]  
Blank MF, 2017, TRANSCR-AUSTIN, V8, P67, DOI 10.1080/21541264.2016.1276658
[8]   SIRT1 Modulation as a Novel Approach to the Treatment of Diseases of Aging [J].
Blum, Charles A. ;
Ellis, James L. ;
Loh, Christine ;
Ng, Pui Yee ;
Perni, Robert B. ;
Stein, Ross L. .
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (02) :417-432
[9]   SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol [J].
Boily, G. ;
He, X. H. ;
Pearce, B. ;
Jardine, K. ;
McBurney, M. W. .
ONCOGENE, 2009, 28 (32) :2882-2893
[10]   Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent [J].
Boocock, David J. ;
Faust, Guy E. S. ;
Patel, Ketan R. ;
Schinas, Anna M. ;
Brown, Victoria A. ;
Ducharme, Murray P. ;
Booth, Tristan D. ;
Crowell, James A. ;
Perloff, Marjorie ;
Gescher, Andreas J. ;
Steward, William P. ;
Brenner, Dean E. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (06) :1246-1252